Cell Physiol Biochem. 2025 Mar 11;59(2):121-130.
ABSTRACT
BACKGROUND/AIMS: Sudden Sensorineural Hearing Loss (SSNHL) is a rapid-onset condition with varied etiologies, creating uncertainty in optimal treatment strategies. This study aimed to assess whether adding pentoxifylline to standard antiviral and steroid therapy could enhance hearing recovery in SSNHL patients.
METHODS: This randomized controlled trial was conducted between January 2021 and June 2023 in a private clinic in Chennai district, Tamil Nadu. Seventy-two patients aged 20-70 years with SSNHL onset within 7 days were randomized to receive either standard therapy (antiviral and steroids) or additional pentoxifylline. Serial pure-tone audiometry was performed to evaluate hearing recovery.
RESULTS: The intervention group showed significantly improved hearing recovery, particularly when treatment was initiated within 72 hours of symptom onset. Non-responders underwent MRI of the brain, revealing cerebellopontine angle pathology in selected cases. Statistical analysis confirmed superior outcomes with pentoxifylline add-on therapy (p < 0.05).
CONCLUSION: Pentoxifylline may enhance hearing recovery when combined with antiviral and steroid therapy in SSNHL, especially when administered early. Intratympanic dexamethasone and MRI are recommended for non-responders.
PMID:41527825
